Skip to main content
. 2020 Nov 6;12:11333–11340. doi: 10.2147/CMAR.S279096

Table 4.

Survival of Patients with Different WBRT Times

Groups No (Case) Intracranial Progression Rate (%) Median IPFS (Months) Median OS (Months)
EGFR-TKI targeted therapy after WBRT(group A) 16 2 (12.5) 13.9 23.9
Synchronize WBRT and EGFR-TKI targeted therapy(group B) 48 9 (18.8) 11.5 20.8
WBRT after EGFR-TKI targeted therapy(group C) 12 4 (33.3) 10.0 17.0
Χ2 value - 1.959 1.008 1.214
P value - 0.376 0.604 0.545